Abstract
Nitrofurantoin lung toxicity was diagnosed among ten patients receiving 50 mg/day to prevent recurrent urinary tract infection. In six patients a symptomatic period of 3-36 months preceded the diagnosis. All but one patient, with irreversible lung injury at presentation recovered completely, five after drug discontinuation and four after steroids therapy. Large amount of data regarding unexpected, sometimes severe pulmonary toxicity during nitrofurantoin therapy should maintain a high index of suspicion for the drug usage among patients with non-resolving pulmonary symptoms. Alternatively, the use of other antimicrobial agents with a better risk-to-benefit ratio should be considered.
Keywords: Lung, nitrofurantoin, toxicity
Current Drug Safety
Title: Nitrofurantoin Pulmonary Toxicity: Neglected Threat
Volume: 5 Issue: 2
Author(s): Emilia Hardak, Gidon Berger, Norberto Krivoy, Anna Solomonov and Mordechai Yigla
Affiliation:
Keywords: Lung, nitrofurantoin, toxicity
Abstract: Nitrofurantoin lung toxicity was diagnosed among ten patients receiving 50 mg/day to prevent recurrent urinary tract infection. In six patients a symptomatic period of 3-36 months preceded the diagnosis. All but one patient, with irreversible lung injury at presentation recovered completely, five after drug discontinuation and four after steroids therapy. Large amount of data regarding unexpected, sometimes severe pulmonary toxicity during nitrofurantoin therapy should maintain a high index of suspicion for the drug usage among patients with non-resolving pulmonary symptoms. Alternatively, the use of other antimicrobial agents with a better risk-to-benefit ratio should be considered.
Export Options
About this article
Cite this article as:
Hardak Emilia, Berger Gidon, Krivoy Norberto, Solomonov Anna and Yigla Mordechai, Nitrofurantoin Pulmonary Toxicity: Neglected Threat, Current Drug Safety 2010; 5 (2) . https://dx.doi.org/10.2174/157488610790936169
DOI https://dx.doi.org/10.2174/157488610790936169 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms
Current Cardiology Reviews PD1/PD-L1 Axis in Uro-oncology
Current Drug Targets New Insights into the Pathogenesis of and Long-Term Risks in Children with Henoch-Schonlein Purpura Nephritis
Current Pediatric Reviews Interleukin-21 in Immune and Allergic Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Perivascular Adipose Tissue Oxidative Stress on the Pathophysiology of Cardiometabolic Diseases
Current Hypertension Reviews Multimodalities Imaging of Immunoglobulin 4-related Cardiovascular Disorders
Current Cardiology Reviews Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO)
Current Vascular Pharmacology Role of Oxidized Phospholipids in Acute Lung Injury
Current Respiratory Medicine Reviews Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Role of Endothelial Progenitor Cell Mobilization After Percutaneous Angioplasty Procedure
Current Pharmaceutical Design Leukocyte Adhesion: A Suitable Target for Anti-Inflammatory Drugs
Current Pharmaceutical Design Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling
Current Pharmaceutical Design Interrelationships Among Gut Microbiota and Host: Paradigms, Role in Neurodegenerative Diseases and Future Prospects
CNS & Neurological Disorders - Drug Targets Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface
Recent Patents on CNS Drug Discovery (Discontinued) Renal Biopsy Research with Implications for Therapy of Glomerulonephritis
Current Drug Therapy Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews Vaccination and Induction of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued)